Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
120.8 EUR | -0.78% | +1.21% | +53.11% |
Apr. 11 | Berenberg Reiterates UCB's Purchase Rating, Raises PT | MT |
Apr. 11 | UCB : Berenberg, Buy, raises its price target | CF |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 49.27 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 4.37 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+53.11% | 24.72B | A | ||
-2.86% | 87.37B | A- | ||
+3.95% | 41.01B | A- | ||
-21.94% | 28.08B | B- | ||
-5.41% | 17.47B | C | ||
-44.23% | 11.69B | B | ||
-17.60% | 11.6B | B- | ||
-13.96% | 11.56B | D+ | ||
-0.22% | 8.44B | B+ | ||
+2.09% | 7.72B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- UCB Stock
- Ratings UCB